Doing More With Less: Capital Efficiency in Drug Development

As the biotechnology industry faces headwinds due to increased regulatory scrutiny and fewer liquidity events, venture capitalists are insisting that companies provide data from “proof-of-concept” experiments before they consider investing. In addition, once companies receive venture funding, they must move their drug candidates to the clinic with minimal equity capital. Experienced biotech executives and venture investors will provide advice on how to improve the chances of getting funded to advance research through the early phases of drug development. More information and online registration is here.